COMPANY PROFILE // THE 014 REPORT
Cumberland Pharmaceuticals Inc.
CPIX (Nasdaq)
Assembled from 1 government source in 0.2 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- InfoUSAspending recipient USFNBCNW7CN4 (matched to this company by exact name) has no entity registration in the SAM.gov public extract of 2026-11-01.possible match
✓ SEC filings✓ State registrationpossible match✗ LEI✗ SAM registration✗ IRS return✗ Website✗ Lobbying registration
No LEI, no SAM registration, no IRS return, no website, no lobbying registration on record.
CUMBERLAND PHARMACEUTICALS INC is an SEC-registered operating company in pharmaceutical preparations, incorporated in TN, based in Nashville,, TN; listed as CPIX (Nasdaq).[source] It reported revenue of $44.5 million for the fiscal year ended 2025-12-31.[source] It has filed 47 documents with the SEC in the last 12 months; the latest is Form 8-K/A, filed 2026-11-16.[source] 25 of 26 lists and sources checked came back clear; the rest are listed with their result.[source]
- red0
- amber0
- info1
- CLEAR25
- POSSIBLE MATCH1
- MATCH0
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- Anthony Todd M. · Vice Pres Organizational Dev (Officer) · latest Form 4 2026-03-20 · filing · LinkedIn search
- Bitterman Chris T. · Vice Pres Sales & Marketing (Officer) · latest Form 4 2026-03-20 · filing · LinkedIn search
- Hamm John M. · VP Chief Financial Officer (Officer) · latest Form 4 2026-03-20 · filing · LinkedIn search
- Herman James L · VP and Chief Compliance Office (Officer) · latest Form 4 2026-03-20 · filing · LinkedIn search
- KAZIMI A J · Chairman and CEO (Director,Officer,10% owner) · latest Form 4 2026-03-20 · filing · LinkedIn search
- Brown Martin S JR · Director · latest Form 4 2026-03-20 · filing · LinkedIn search
- Galante Joseph C · Director · latest Form 4 2026-03-20 · filing · LinkedIn search
- Jones James · Director · latest Form 4 2026-03-20 · filing · LinkedIn search
- Krogulski Kenneth · Director · latest Form 4 2026-03-20 · filing · LinkedIn search
- Young Caroline · Director · latest Form 4 2026-03-20 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 25 CLEAR, 1 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001087294 | source |
| UEIpossible match | USFNBCNW7CN4 | source |
| EIN | 62-1765329 | source |
| NY DOS ID | 7160755 | record |
| Business address (SEC) | 1600 WEST END AVENUE, SUITE 1300, NASHVILLE,, TN, 37203 | source |
Does not exist in the records we hold: LEI, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-03-31 · in 129 days · Next 10-K due (period ended 2026-12-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 174 days · Next 10-Q due (period ended 2027-03-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2834 (pharmaceutical preparations): 568 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- PFIZER INC · 124 SEC filings in 12 months · $25.74B federal (possible match)
- Merck & Co., Inc. · 150 SEC filings in 12 months · $13.51B federal (possible match)
- ABBOTT LABORATORIES · 118 SEC filings in 12 months · 1 flag · $2.64B federal (possible match)
- ASTRAZENECA PLC · 140 SEC filings in 12 months · $602.8M federal (possible match)
- TEVA PHARMACEUTICAL INDUSTRIES LTD · 168 SEC filings in 12 months · $77.6M federal (possible match)
- NOVARTIS AG · 34 SEC filings in 12 months · $41.9M federal (possible match)
- Spero Therapeutics, Inc. · 41 SEC filings in 12 months · 4 flags · $39.5M federal (possible match)
- Grifols SA · 18 SEC filings in 12 months · $22.5M federal (possible match)
- SCYNEXIS INC · 54 SEC filings in 12 months · 3 flags · $18.5M federal (possible match)
- Ensysce Biosciences, Inc. · 45 SEC filings in 12 months · 3 flags · $15.1M federal (possible match)
- UNITED THERAPEUTICS Corp · 454 SEC filings in 12 months · 2 flags · $6.8M federal (possible match)
- Zoetis Inc. · 144 SEC filings in 12 months · 1 flag · $6.7M federal (possible match)
ADDRESS · ZIP CODE
Location context
At the same address (7)
- SKYNYRD FOUNDATION · IRS-registered organization
- S O L I D · IRS-registered organization
- CHECOTAH ANIMAL TOWN & SCHOOL CATS FOUNDATION · IRS-registered organization
- COWART FAMILY CHARITABLE FOUNDATION · IRS-registered organization
- CUMBERLAND PHARMA FOUNDATION · IRS-registered organization
- AMERICAN INNS OF COURT FOUNDATION · IRS-registered organization
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-16 filing 8-K/A items 9.01 · SEC EDGAR
- 2026-11-16 filing 8-K/A items 9.01 · SEC EDGAR
- 2026-11-13 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-10 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-10-26 filing 8-K items 7.01,8.01 · SEC EDGAR
- 2026-10-23 filing 8-K items 8.01 · SEC EDGAR
- 2026-09-11 filing 8-K/A items 5.07 · SEC EDGAR
- 2026-08-28 filing 8-K items 7.01 · SEC EDGAR
- 2026-08-07 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-04 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-07-13 filing 8-K items 8.01 · SEC EDGAR
- 2026-07-01 officer change 8-K items 1.01,1.02,2.01,5.02,8.01,9.01 · SEC EDGAR
- 2026-06-25 filing 8-K items 5.07 · SEC EDGAR
- 2026-05-26 filing DEFM14A · SEC EDGAR
- 2026-05-15 filing PREM14A · SEC EDGAR
- 2026-05-08 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-05-05 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-04-24 filing 8-K items 5.07 · SEC EDGAR
- 2026-04-23 filing DEFA14A · SEC EDGAR
- 2026-04-23 filing 8-K items 1.01,7.01,8.01,9.01 · SEC EDGAR
- 2026-03-20 insider First Form 3/4/5 on record for Anthony Todd M. (Vice Pres Organizational Dev) · SEC Forms 3/4/5
- 2026-03-20 insider First Form 3/4/5 on record for Bitterman Chris T. (Vice Pres Sales & Marketing) · SEC Forms 3/4/5
- 2026-03-20 insider First Form 3/4/5 on record for Hamm John M. (VP Chief Financial Officer) · SEC Forms 3/4/5
- 2026-03-20 insider First Form 3/4/5 on record for Herman James L (VP and Chief Compliance Office) · SEC Forms 3/4/5
- 2026-03-20 insider First Form 3/4/5 on record for Brown Martin S JR (Director) · SEC Forms 3/4/5
- 2026-03-20 insider First Form 3/4/5 on record for Galante Joseph C (Director) · SEC Forms 3/4/5
- 2026-03-12 filing ARS · SEC EDGAR
- 2026-03-09 filing DEFA14A · SEC EDGAR
- 2026-03-09 filing Proxy statement · SEC EDGAR
- 2026-03-09 filing Annual report (10-K) · SEC EDGAR
112 earlier entries
- 2026-03-03 filing 8-K items 2.02,9.01
- 2026-02-04 filing 8-K items 8.01
- 2025-11-24 filing 8-K items 1.01,2.03
- 2025-11-07 filing Quarterly report (10-Q)
- 2025-11-04 filing 8-K items 2.02,9.01
- 2025-10-21 filing 8-K items 8.01
- 2025-08-25 filing UPLOAD
- 2025-08-15 filing CORRESP
- 2025-08-08 filing Quarterly report (10-Q)
- 2025-08-05 filing 8-K items 2.02,9.01
- 2025-08-04 filing UPLOAD
- 2025-05-09 filing Quarterly report (10-Q)
- 2025-05-06 filing 8-K items 2.02,9.01
- 2025-04-28 filing 8-K items 5.07
- 2025-04-04 insider First Form 3/4/5 on record for KAZIMI A J (Chairman and CEO)
- 2025-04-04 insider First Form 3/4/5 on record for Jones James (Director)
- 2025-04-04 insider First Form 3/4/5 on record for Krogulski Kenneth (Director)
- 2025-04-04 insider First Form 3/4/5 on record for Young Caroline (Director)
- 2025-03-19 filing 8-K items 8.01
- 2025-03-18 filing ARS
- 2025-03-10 filing DEFA14A
- 2025-03-10 filing Proxy statement
- 2025-03-07 filing Annual report (10-K)
- 2025-03-04 filing 8-K items 2.02,9.01
- 2025-02-19 filing 8-K items 8.01
- 2025-02-14 filing 424B5
- 2025-02-14 filing 8-K items 8.01,9.01
- 2025-02-04 filing 8-K items 8.01
- 2024-12-09 filing 8-K items 8.01
- 2024-11-12 filing 8-K items 8.01
- 2024-11-08 filing Quarterly report (10-Q)
- 2024-11-07 filing 8-K items 2.02,9.01
- 2024-11-06 filing 8-K items 8.01
- 2024-11-04 filing 8-K items 8.01
- 2024-08-09 filing Quarterly report (10-Q)
- 2024-08-06 filing 8-K items 2.02,9.01
- 2024-05-10 filing Quarterly report (10-Q)
- 2024-05-07 filing 8-K items 2.02,9.01
- 2024-04-29 filing 8-K items 5.07
- 2024-03-22 filing ARS
- 2024-03-20 filing 8-K items 8.01,9.01
- 2024-03-20 filing 424B5
- 2024-03-13 filing DEFA14A
- 2024-03-13 filing Proxy statement
- 2024-03-13 filing Annual report (10-K)
- 2024-03-05 filing 8-K items 2.02,9.01
- 2023-12-26 filing EFFECT
- 2023-12-21 filing CORRESP
- 2023-12-19 filing UPLOAD
- 2023-12-15 filing DEL AM
- 2023-12-14 filing S-3
- 2023-11-13 filing Quarterly report (10-Q)
- 2023-11-07 filing 8-K items 2.02,9.01
- 2023-10-13 filing 8-K items 8.01,9.01
- 2023-09-06 filing 8-K items 1.01,1.02,2.03,9.01
- 2023-08-11 filing Quarterly report (10-Q)
- 2023-08-08 filing 8-K items 2.02,9.01
- 2023-06-30 filing 8-K items 8.01
- 2023-06-22 filing 8-K items 8.01
- 2023-06-07 filing 8-K items 8.01
- 2023-06-02 filing 8-K items 4.01
- 2023-05-24 filing 8-K items 4.01
- 2023-05-16 filing 8-K items 8.01
- 2023-05-16 filing S-8
- 2023-05-12 filing Quarterly report (10-Q)
- 2023-05-09 filing 8-K items 2.02,9.01
- 2023-04-28 filing 8-K items 5.07
- 2023-04-17 filing 8-K items 8.01
- 2023-04-04 filing 8-K items 8.01
- 2023-03-22 filing ARS
- 2023-03-15 filing DEFA14A
- 2023-03-15 filing Proxy statement
- 2023-03-15 officer change 8-K items 5.02,9.01
- 2023-03-13 filing Annual report (10-K)
- 2023-03-07 filing 8-K items 2.02,9.01
- 2023-01-17 officer change 8-K items 5.02
- 2022-12-12 filing 8-K items 8.01
- 2022-11-14 filing Quarterly report (10-Q)
- 2022-11-08 filing 8-K items 2.02,9.01
- 2022-08-12 filing Quarterly report (10-Q)
- 2022-08-09 filing 8-K items 2.02
- 2022-07-19 officer change 8-K items 5.02
- 2022-06-03 officer change 8-K items 5.02
- 2022-05-13 filing Quarterly report (10-Q)
- 2022-05-10 filing 8-K items 2.02,9.01
- 2022-05-03 filing 8-K items 5.07
- 2022-04-25 filing 8-K items 8.01
- 2022-03-22 officer change 8-K items 5.02
- 2022-03-17 filing 8-K/A items 9.01
- 2022-03-17 officer change 8-K items 5.02,9.01
- 2022-03-16 filing Proxy statement
- 2022-03-11 filing Annual report (10-K)
- 2022-03-08 filing 8-K items 2.02,9.01
- 2022-01-06 filing 8-K items 1.01,2.01,7.01,9.01
- 2022-01-03 filing 8-K items 1.01
- 2021-12-27 filing 8-K items 8.01,9.01
- 2021-12-27 filing 424B5
- 2021-12-01 filing 8-K items 8.01
- 2021-11-19 filing 8-K items 1.01,2.03,7.01,9.01
- 2021-11-12 filing Quarterly report (10-Q)
- 2021-11-09 filing 8-K items 2.02,9.01
- 2021-11-01 filing 8-K items 1.01
- 2021-08-13 filing Quarterly report (10-Q)
- 2021-08-10 filing 8-K items 2.02
- 2021-06-14 filing 8-K items 1.01
- 2021-05-14 officer change 8-K items 5.02
- 2021-05-14 filing Quarterly report (10-Q)
- 2021-05-11 filing 8-K items 2.02,9.01
- 2021-04-30 filing 8-K items 5.07
- 2021-03-15 filing Proxy statement
- 2021-03-12 filing Annual report (10-K)
- 2021-03-09 filing 8-K items 2.02,9.01
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-16 (within 7 days) 8-K/A filed: Item 9.01 exhibits
- 2026-11-16 (within 7 days) 8-K/A filed: Item 9.01 exhibits
- 2026-11-13 (within 30 days) 10-Q filed
- 2026-11-10 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-10-26 (within 30 days) 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event
- 2026-10-23 (within 30 days) 8-K filed: Item 8.01 other event
- 2026-09-11 (older) 8-K/A filed: Item 5.07 shareholder vote
- 2026-08-28 (older) 8-K filed: Item 7.01 Regulation FD disclosure
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-21; the colour is also written out in words.
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:CPIX The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
6 possible matches held apart, matched by name only, not counted above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1087294 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | CPIX / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| EIN | 621765329 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001087294 | SEC EDGAR / IRS |
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Revenue (fiscal year ended 2025-12-31) | $44,521,431 | 2025-12-31 | 10-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax | as filed | 2026-11-21 23:59 UTC | Report an error |
| Net income (loss) (fiscal year ended 2025-12-31) | -$2,836,128 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-21 23:59 UTC | Report an error |
| Total assets (at 2025-12-31) | $76,823,992 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-21 23:59 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $24,880,322 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-21 23:59 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $11,444,693 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-21 23:59 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-21 23:59 UTC | Report an error |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-21 23:59 UTC | Report an error |
| State of incorporation | TN | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-21 23:59 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-21 23:59 UTC | Report an error |
| Business address | 1600 WEST END AVENUE, SUITE 1300, NASHVILLE,, TN, 37203 | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-21 23:59 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-21 23:59 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | $4,932,522 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-21 23:59 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $97,903 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-21 23:59 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $4,939,739 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-21 23:59 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-13 · accession 0001087294-26-000079
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Revenue | $2,156,356 | 3 months ended 2026-09-30 | 10-Q | 2026-11-13 | 0001087294-26-000079 | 2026-11-21 23:59 UTC | Report an error |
| Net income (loss) | $77,776,986 | 3 months ended 2026-09-30 | 10-Q | 2026-11-13 | 0001087294-26-000079 | 2026-11-21 23:59 UTC | Report an error |
| Interest expense | $4,604 | 3 months ended 2026-09-30 | 10-Q | 2026-11-13 | 0001087294-26-000079 | 2026-11-21 23:59 UTC | Report an error |
| Cash and cash equivalents | $80,581,021 | at 2026-09-30 | 10-Q | 2026-11-13 | 0001087294-26-000079 | 2026-11-21 23:59 UTC | Report an error |
| Contract liabilities, current (from an earlier report) | $25,000 | at 2025-12-31 | 10-K | 2026-03-09 | 0001087294-26-000020 | 2026-11-21 23:59 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-16 Filing 8-K/A filed: Item 9.01 exhibits
- 2026-11-16 Filing 8-K/A filed: Item 9.01 exhibits
- 2026-11-13 Filing 10-Q filed
- 2026-11-10 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-10-26 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event
- 2026-10-23 Filing 8-K filed: Item 8.01 other event
- 2026-09-11 Filing 8-K/A filed: Item 5.07 shareholder vote
- 2026-08-28 Filing 8-K filed: Item 7.01 Regulation FD disclosure
- 2026-08-07 Filing 10-Q filed
- 2026-08-04 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-07-13 Filing 8-K filed: Item 8.01 other event
- 2026-07-01 Filing 8-K filed: Item 1.01 material agreement; Item 1.02 agreement terminated; Item 2.01 acquisition or disposition; Item 5.02 officer or director change; Item 8.01 other event; Item 9.01 exhibits
- 2026-06-25 Filing 8-K filed: Item 5.07 shareholder vote
- 2026-05-26 Filing DEFM14A filed
- 2026-05-15 Filing PREM14A filed
- 2026-05-08 Filing 10-Q filed
- 2026-05-05 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-04-24 Filing 8-K filed: Item 5.07 shareholder vote
- 2026-04-23 Filing DEFA14A filed
- 2026-04-23 Filing 8-K filed: Item 1.01 material agreement; Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-03-12 Filing ARS filed
- 2026-03-09 Filing DEFA14A filed
- 2026-03-09 Filing DEF 14A filed
- 2026-03-09 Filing 10-K filed
- 2026-03-03 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
8-K item text, as filed (excerpts)
- 2026-11-10 8-K Item 2.02, Results of Operations and Financial Condition
On November 10, 2026 , Cumberland Pharmaceuticals Inc. (the "Company") issued a press release which provided a company update and the financial results for the three and nine months ended September 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02. This information is furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, unless specifically incorporated by reference in a document filed under the Securities Act of… the 8-K · retrieved 2026-11-21 23:59 UTC - 2026-10-26 8-K Item 7.01, Regulation FD Disclosure
On October 26, 2026, Cumberland Pharmaceuticals Inc. (the “Company” or “Cumberland”), an innovation-focused biopharmaceutical company developing new products for rare diseases, issued a press release providing an update on its ifetroban product candidate, which is in development as a potential treatment for the cardiomyopathy associated with Duchenne muscular dystrophy ("DMD"). A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The information furnished in this Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”)… the 8-K · retrieved 2026-11-21 23:59 UTC - 2026-10-26 8-K Item 8.01, Other Events
On October 26, 2026, the Company provided an update on its ifetroban product candidate in development as a potential treatment for the cardiomyopathy associated with DMD. The Company announced plans to submit a New Drug Application ("NDA") to the U.S. Food and Drug Administration (the “FDA”) for ifetroban as a treatment for the cardiomyopathy associated with DMD. The decision to file the NDA for a Traditional Approval follows a pre-NDA meeting held this fall with the FDA. The planned submission will include data from the Company’s FIGHT DMD™ clinical study and its ongoing open-label extension, data from two natural history databases of DMD patients, preclinical data published in the Journal… the 8-K · retrieved 2026-11-21 23:59 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
POSSIBLE MATCHES · GROUPED BY SOURCE8. Enforcement by agency
DOJ and agency corporate enforcement (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchCumberland Pharmaceuticals Inc · exact legal name · sx:enf:secap:34-98553 Compare
Each record's own page holds its date and the agency document. Matched by exact name only; none of these is counted in the headline.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
5 state and city records carry this company's exact name, from 4 sources. Possible matches only.
State licences (2)
possible match: matched by name only, not merged (2)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchCUMBERLAND PHARMACEUTICALS · exact name match to 'CUMBERLAND PHARMACEUTICALS INC' (no other entity shares the name) · sx:elic:ctcred:2536967 Compare
- possible matchCUMBERLAND PHARMACEUTICALS · exact name match to 'CUMBERLAND PHARMACEUTICALS INC' (no other entity shares the name) · sx:elic:ctcred:1990478 Compare
ClinicalTrials.gov (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchCumberland Pharmaceuticals · exact name match to 'CUMBERLAND PHARMACEUTICALS INC' (no other entity shares the name) · sx:ctgov:h1ff931e3356df93b Compare
New York corporations (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchCUMBERLAND PHARMACEUTICALS INC. · exact legal name · sx:nydos:7160755 Compare
USAspending (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchCUMBERLAND PHARMACEUTICALS INC · exact legal name · sx:usaspending:USFNBCNW7CN4 Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1087294.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001087294. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.